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Abstract: Engineered nanomaterials have been developed for widespread applications due 
to many highly unique and desirable characteristics. The purpose of this study was to 
assess pulmonary inflammation and subepicardial arteriolar reactivity in response to  
multi-walled carbon nanotube (MWCNT) inhalation and evaluate the time course of 
vascular alterations. Rats were exposed to MWCNT aerosols producing pulmonary 
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deposition. Pulmonary inflammation via bronchoalveolar lavage and MWCNT 
translocation from the lungs to systemic organs was evident 24 h post-inhalation.  
Coronary arterioles were evaluated 24–168 h post-exposure to determine microvascular 
response to changes in transmural pressure, endothelium-dependent and -independent 
reactivity. Myogenic responsiveness, vascular smooth muscle reactivity to nitric oxide,  
and α-adrenergic responses all remained intact. However, a severe impact on  
endothelium-dependent dilation was observed within 24 h after MWCNT inhalation, a 
condition which improved, but did not fully return to control after 168 h. In conclusion, 
results indicate that MWCNT inhalation not only leads to pulmonary inflammation and 
cytotoxicity at low lung burdens, but also a low level of particle translocation to systemic 
organs. MWCNT inhalation also leads to impairments of endothelium-dependent dilation 
in the coronary microcirculation within 24 h, a condition which does not fully dissipate 
within 168 h. The innovations within the field of nanotechnology, while exciting and 
novel, can only reach their full potential if toxicity is first properly assessed. 
Keywords: microcirculation; coronary; arteriole; nanotoxicology; multi-walled carbon 
nanotube; engineered nanomaterial; translocation 
 
1. Introduction 
Engineered nanomaterials (ENM), are anthropogenic materials specifically designed for their 
unique properties at the nanometer scale (<100 nm in one dimension) [1,2]. The uses for these 
materials are seemingly limitless, with an impressive amount of resources aimed at the development of 
engineering and biomedical applications [3]. ENM range widely with respect to physiochemical 
properties, including but not limited to size, shape, charge, solubility, free radical production, 
biological half-life, and functionalization leading to physiological responses after exposure [4]. They 
can be loaded, bound, or impregnated with a variety of pharmaceutical compounds, gene plasmids, or 
heavy metals, thereby, acting as vehicles for intentional biomedical therapeutic exposure [5]. However, 
ENM exposures may also occur unintentionally in the manufacturing process, as a by-product of their 
use, or during their breakdown [6]. Nanotechnology advancements, while exciting and novel, can only 
reach their full potential if the toxicity is first assessed. 
Multi-walled carbon nanotubes (MWCNT) have been developed for widespread applications, 
including biomedical, electronic, computer, and aerospace products, due to their highly desirable 
mechanical, electrical, thermal, strength, and magnetic properties. The physical composition and 
inherent design of MWCNT allow for variation in the length or width of MWCNT, leading to an 
alteration of the surface area available for drug delivery, or an increase in tensile strength [7]. These 
spear-like carbon compounds have been shown to embed in alveolar tissue [8], producing alarmingly 
analogous results to asbestos exposure [9,10], as the body has considerable difficulties clearing such 
fibrous particles [11]. Filamentously shaped MWCNT have been demonstrated to penetrate alveolar 
macrophages, epithelial cells [9], pleural cells, and interstitial cells; followed closely by macrophage 
accumulation, an increase in oxidant production [12], the development of progressive pulmonary 
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fibrosis, and chronic granulomatous inflammation producing a rapid and detrimental result after 
pulmonary exposure [13]. However, these results exclusively pertain to interactions within the 
pulmonary system, while the microvascular impacts remained unexamined.  
Questions pertaining to the in vivo physiochemical properties of the MWCNT are also 
physiologically relevant as carbon nanomaterials have been shown to slowly translocate after 
pulmonary exposure to secondary target organs, a potentially hazardous outcome associated with 
exposure [14,15]. Studies have also been conducted to evaluate the extra-pulmonary secondary target 
organ effects after pulmonary exposure to MWCNT demonstrating a dose-dependent inflammation 
and necrosis within the liver and kidney [12], a reduction in antioxidant capacity [16], and indirect 
thrombogenic effects within the liver and heart [17]. Therefore, microvascular dysfunction resulting 
from MWCNT exposure due to translocation, secondary systemic inflammation, or an increased 
oxidant production associated with direct contact is plausible.  
We have reported that on an equal mass basis pulmonary exposures to nano-sized titanium dioxide 
(TiO2) particles produced greater endothelium-dependent microvascular dysfunction than exposure to 
fine titanium dioxide particles [18]. Recent investigations in our laboratory have also determined that 
these endothelium-dependent effects are primarily associated with decreased nitric oxide (NO) 
bioavailability related to increased oxidative stress in the arteriolar wall leading to alterations in 
prostanoid signaling [19,20].  
Our previous ENM exposure investigations have focused on TiO2, a spherical metal oxide, and 
explored its impact on systemic and coronary microvascular function. The purpose of this study was to 
evaluate pulmonary inflammation and subepicardial arteriolar reactivity after MWCNT inhalation, a 
fibrous carbon nanomaterial. A second purpose was to evaluate the time course of impairment  
post-inhalation. We hypothesized that MWCNT exposure would initially compromise coronary 
function, characterized by alterations in arteriolar reactivity, after acute exposure, and that this 
dysfunction would dissipate with time post-exposure. 
2. Results and Discussion 
2.1. Experimental Characterization 
2.1.1. MWCNT Aerosol Characteristics 
There were no differences between the MWCNT exposure conditions that each group was exposed 
to with respect to aerosol concentration and calculated lung burden (Table 1). These results represent 
the reliability and repeatability of our inhalation exposure system, while indicating that temporal 
differences in microvascular reactivity were not due to differential initial dosages.  
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Table 1. Exposure and dosage characteristics of control and multi-walled carbon nanotube 
(MWCNT) exposed rats. 
Time Post Inhalation N Aerosol Concentration × Time ((mg/m3) × h) Lung Burden (µg/lung) 
Control 11 0 0 
24 h 16 23 ± 1 12.6 ± 1.4 
72 h 8 26 ± 1 14.3 ± 1.6 
120 h 9 23 ± 1 12.6 ± 1.4 
168 h 12 24 ± 1 13.1 ± 1.4 
2.1.2. Animal and Vessel Characteristics 
There were no significant differences with respect to age, weight, heart wet weight, or mean arterial 
pressure (MAP) after initial MWCNT exposure or over time after exposure (Table 2). Additionally, 
there were no significant differences within the vessel characteristics of spontaneous arteriolar  
tone, maximal diameter, and active tone (Table 2). Overall, these results suggest that the basal 
characteristics of the rats and coronary arterioles were unaffected by MWCNT exposure.  
Table 2. Animal and arteriolar characteristics of control and MWCNT exposed rats. 
Time Post 
Inhalation 
N 
Age  
(weeks) 
Weight 
(g) 
MAP  
(mm Hg) 
Heart  
Wet Weight 
(g) 
Active 
Diameter 
(µm) 
Passive 
Diameter 
(µm) 
Active 
Tone  
(%) 
Control 11 8.4 ± 0.2 350 ± 4 111 ± 7 1.17 ± 0.03 96 ± 7 128 ± 7 25 ± 2 
24 h 16 8.7 ± 0.2 343 ± 4 105 ± 3 1.12 ± 0.02 100 ± 4 131 ± 5 23 ± 2 
72 h 9 8.7 ± 0.2 349 ± 4 105 ± 4 1.18 ± 0.03 109 ± 6 141 ± 4 23 ± 3 
120 h 10 9.1 ± 0.1 364 ± 3 108 ± 6 1.16 ± 0.03 97 ± 7 129 ± 7 25 ± 4 
168 h 12 9.2 ± 0.1 357 ± 12 112 ± 2 1.17 ± 0.02 105 ± 7 136 ± 5 24 ± 3 
2.2. Pulmonary Inflammation and Damage 
MWCNT inhalation caused pulmonary inflammation and damage as determined by significant 
increases in polymorphonuclear leukocytes (PMN) harvested by bronchoalveolar lavage (BAL) 
(Figure 1a) and in lactate dehydrogenase (LDH) activity (cell damage) (Figure 1b). Protein (air/blood 
barrier damage) (Figure 1c) in BAL fluid exhibited non-significant increases of 40% after MWCNT 
exposure. Pulmonary responses remained relatively constant at lung burdens from 13.5 to 54.1 ug/lung. 
These data indicate that pulmonary inflammation and cellular damage occurred within 24 h of 
MWCNT inhalation even at a low lung burden of 13.5 µg/lung. 
Mouse aspiration studies from our group reported that MWCNT causes acute lung inflammation 
and damage at lung burdens of 10–80 μg/mouse. In addition, granulomatous lesions and interstitial 
fibrosis which persisted for at least 56-days were reported at lung burdens of 20–80 μg/mouse [8,9,21]. 
This study is similar to previous results indicating pulmonary inflammation and cytotoxicity at low 
lung burdens of ENM exposure [22–25]. 
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Figure 1. Comparison of pulmonary inflammation markers induced by inhalation exposure 
to 5 mg/m3 multi-walled carbon nanotube for 5 h per day for 1, 3, or 4 days. (a) Cell counts 
of polymorphonuclear leukocytes were used as an indicator of inflammation. Values are 
given as means ± SE (n = 8). * indicates that PMN influx for that group was significantly 
higher than control (p < 0.05). (b) Bronchoalveolar lavage fluid lactate dehydrogenase 
(LDH) was used as a marker of cytotoxicity. Values are given as means ± SE (n = 8).  
* indicates that LDH activity for that group was significantly higher than control  
(p < 0.05). (c) Bronchoalveolar lavage fluid albumin concentrations were used as a marker 
of alveolar air/blood barrier damage. Values are given as means ± SE (n = 8). 
 
In comparison to rat verses human exposures, the equivalent human lung dose is approximately  
3.4 mg [26]. This dosage is not considered substantial, as burdens in the human lung considered 
pathological are in the multiple gram range for known toxicants (silica, coal dust, etc.). 
When comparing pulmonary inflammatory responses across several particle types (fine TiO2 [27], 
fine ROFA [27], ultrafine TiO2 [22], or MWCNT) at dosages ranging from 13.5 µg/rat in this study to 
250 µg/rat fine ROFA examined by this group, the potency sequence was MWCNT > ultrafine  
TiO2 > fine ROFA = fine TiO2. Therefore, MWCNT evaluated in this study lead to the greatest 
pulmonary inflammatory outcome at the lowest toxicological dosage.  
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2.3. Multi-Walled Carbon Nanotube Translocation 
Enhanced darkfield imaging of lung sections readily demonstrated MWCNT in lung sections as 
illustrated in Figure 2a. Deposited MWCNT structures in the lungs ranged from singlet fibers to larger 
structures containing many CNT. MWCNT were also identified in the three systemic organs (kidney, 
liver, heart) examined. In all cases the extra-thoracic MWCNT were single fibers, 3–6 microns in 
length. Figure 2b shows an example of a MWCNT in the kidney.  
Figure 2. Enhanced darkfield imaging of MWCNT within the lung (a) and the kidney (b). 
MWCNT appear under enhanced darkfield as bright white structures.  
 
Transport of MWCNT to systemic organs expressed in terms of MWCNT fibers and in terms of a 
percentage of total lung burden for the kidney, liver, and heart are given in Table 3. The liver, which is 
also the largest organ of the three examined, had the largest number of fibers; the heart, the smallest 
(a)   
(b)   
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organ, had the fewest fibers. Translocation of MWCNT from the lung to each systemic organ was a 
small fraction of one percent over the 24 h post-exposure period.  
Table 3. Systemic MWCNT translocation from the lungs 24 h after inhalation exposure. 
Systemic Distribution of Inhaled Multi-Walled Carbon Nanotubes 1 
Organ # of MWCNT Fibers 2 % Lung Burden 
Lung 646.8 × 106 * 99.99890 
Kidney 1533 ± 530 0.00024 
Liver 4535 ± 1100 0.00070 
Heart 525 ± 1260 † 0.00008 
1 Total lung burden of MWCNT following inhalation was 13.2 µg; 2 Conversion from weight of MWCNT to 
number of MWCNT was based on a value of 49 million MWCNT fibers per microgram [28]. Data are  
Mean ± SE for an N of 6 animals. * or † indicates p < 0.05 vs. other organs. 
MWCNT have been shown to translocate from the lungs after inhalation or intratracheal instillation, 
in this report and others, indicating the possibility for direct systemic vascular interaction [12]. In this 
study, we found a small number of MWCNT within the liver, kidney, heart 24 h after pulmonary 
exposure. It is reasonable to expect to find some translocated MWCNT in the kidney, a clearance 
organ, in preparation to eliminate the ENM. MWCNT found within the liver may not be representative 
of the number throughout systemic organs, as the liver is a larger sequestering organ. Given the 
heterogeneity in organ function, size, and anatomy a true count of MWCNT number may prove not 
only difficult, but misleading. For example, the impact of MWCNT within the heart would be very 
different than those found in the liver and kidney, as coronary function is based on cellular signaling, 
pathways, and interactions all operating in unison. Therefore, a single MWCNT piercing the small 
delicate concert of the impulse-generating cells could contribute to significant untoward consequences. 
The concept of direct interaction due to translocation is not unique to MWCNT, as other materials 
after pulmonary exposure have also been found systemically [15,29–32].  
Translocation from the lung is not the only avenue for direct ENM contact. Other intentional  
non-pulmonary routes of exposure (intravenous injection for biomedical drug delivery or imaging) 
must be considered. This direct interaction may play a role in alterations to endothelium-dependent 
signaling patterns, as endothelial cells may be injured due to intimate contact [8], heightened 
inflammatory response [33], induction of ENM-driven NO scavenging [34], and an increase in reactive 
species (oxidative or nitrosative) [35]. 
MWCNT have been shown to produce a direct biological effect both in vitro and in vivo. In  
co-culture, endothelial and epithelial cells have shown an increase in pro-inflammatory signaling  
and cytokine production (including NF-κB, IL-6, and IL-8), an enhancement of MAP kinase 
phosphorylation, a disruption of cellular cytoskeleton, severe functional impairments, and a reduction 
in cellular viability [10,36–38]. Walk et al. [37] also reported that these endothelial outcomes may be 
dependent on the MWCNT dose. Furthermore, in vivo MWCNT exposure, at higher concentrations 
than those described within this study, has led to other outcomes independent of pulmonary  
outcomes including increases in hepatic platelet adhesion, fibrinogen deposition, increase in vascular 
permeability, systemic inflammation, and decreased anti-oxidant capabilities [16,17,39]. The decrease 
in anti-oxidant enzyme activity could lead to an increase in oxidant stress and subsequent NO 
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scavenging [16]. Additionally, increases in platelet adhesion may induce thromboxane A2 generation, 
thereby creating a vasoconstrictive environment [17]. 
2.4. Coronary Isolated Microvessel Reactivity 
2.4.1. Endothelium-Dependent Responses 
Endothelium-dependent dilator responses were significantly attenuated in subepicardial arterioles 
following pulmonary exposure to MWCNT. This impairment was evident 24 h post-exposure (7% at 
10−9 M ACh to 87% at 10−4 M ACh from control) and remained blunted through 168 h post-exposure 
(17% at 10−9 M ACh to 57% at 10−4 M ACh from control) (Figure 3). Vascular reactivity to ACh was 
impaired to such a degree that vasoconstriction ensued at the highest ACh dose (1 × 10−4), indicating a 
shift in mechanistic signaling.  
Figure 3. Acetylcholine time-course dose response curve at 24–168 h after control  
(n = 8 rats) or MWCNT inhalation (n = 7–14 rats). Values are mean ± SE.  
* p < 0.05 vs. Control. † p < 0.05 for 24 h compared to all other groups. MWCNT 
inhalation attenuates coronary arteriolar endothelium-dependent dilation. 
 
With respect to the Ca2+ ionophore A23187, endothelium-dependent reactivity was similarly 
blunted throughout the dosages (1 × 10−9–1 × 10−5 M) at the 24 h time point (18% at 10−9 M A23187 
to 73% at 10−5 M A23187 from control) (Figure 4). These results indicate that MWCNT inhalation 
impairs endothelium-dependent dilation 24 h post-exposure. Although this impairment dissipated over 
time, normal reactivity did not fully return to control levels even after 168 h post-inhalation (12% at 
10−9 M A23187 to 17% at 10−4 M A23187 from control).  
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Figure 4. A23187 time-course dose response curve 24–168 h after control (n = 6 rats)  
or MWCNT inhalation (n = 6–12 rats). Values are mean ± SE. * p < 0.05 vs. Control.  
† indicates p < 0.05 24 h compared to all other groups. Time course of impaired 
endothelium-dependent dilation in coronary arterioles after MWCNT inhalation. 
 
Endothelium-dependent dilation was examined via two pathways: ACh and A23187 Ca2+ signaling. 
Differences in either pathway may be attributed to a decrease in nitric oxide bioavailability, due to 
reduced production or oxidative scavenging of NO. While, A23187 operates via an increase in 
intracellular Ca2+ for signal transduction, the ACh results may indicate acute shifts in NO 
bioavailability in combination with compensatory arachidonic acid metabolites (prostacyclin, 
thromboxane A2, lipoxygenase) leading to the lack of reactivity exhibited at the 24 h time point. 
Regardless of the agonist, this poor endothelial reactivity may be indicative of competing vasoactive 
metabolites, a decrease in dilation due to NO bioavailability, or an increase in the potent vasoconstrictor 
thromboxane A2. Collectively, this may lead to an acute blunting of endothelium-dependent dilation 
24 h after MWCNT exposure. As time passes post-exposure, endothelium-dependent dilation  
slowly improves with respect to both ACh and A23187 responses, but neither regained full reactivity 
back to control levels within 168 h post exposure. These signaling alterations can be seen in a  
number of cardiovascular disease states, but have only recently been described in response to ENM 
exposure [18,19,40–44]. 
The results described in this manuscript differ from past microvascular results to TiO2 exposure. 
Both ENM exposures impaired endothelium-dependent dilation within 24 h; however, TiO2inhalation 
attenuated dilation to ACh and A23187, while MWCNT inhalation leads to a constriction in response 
to ACh and a blunted response to A23187 [18,19,41]. These results indicate inhalation of either 
nanomaterial (TiO2 or MWCNT) will impair endothelium-dependent dilation; however, the pathway 
and severity of said impairment is unique and specific to each ENM. In these early studies, it appears 
that both TiO2 and MWCNT impact endothelium-dependent reactivity associated with NO signaling, 
indicated by the impairment of dilation in response to A23187. MWCNT inhalation may also impact 
arachidonic acid signaling through ACh dose response, possibly to a greater degree than TiO2 
inhalation, as evident by the constriction at higher doses of ACh not seen after TiO2 inhalation. 
Interestingly, when comparing microvascular endothelium-dependent dilation inhibition across  
several particle types and dosages investigated by our group, the potency sequence is very similar  
to that for inflammation, i.e., MWCNT > ultrafine TiO2 > fine ROFA = fine TiO2 [20,24]. Therefore,  
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MWCNT induced the greatest pulmonary inflammation and the greatest inhibition of  
endothelium-dependent dilation. 
2.4.2. Vascular Smooth Muscle Responsiveness 
Sodium nitroprusside (SNP) was used as an NO donor to evaluate endothelium-independent 
vasodilation. There were no significant differences between the groups, indicating that MWCNT 
exposure does not alter vascular smooth muscle NO sensitivity in the coronary microcirculation 
(Figure 5). 
Figure 5. Sodium nitroprusside time-course dose response curve 24–168 h after control  
(n = 8 rats) or MWCNT inhalation (n = 7–8 rats).Values are mean ± SE. MWCNT 
inhalation does not impair microvascular reactivity of smooth muscle to NO signaling. 
 
Phenylephrine (PE) was used to evaluate vascular smooth muscle α-adrenergic sensitivity. There 
were no significant differences associated with coronary arteriolar constriction, with respect to time, 
due to MWCNT exposure (Figure 6a), i.e., the dose response curve between these groups was not 
significantly different (p = 0.08). However, statistical significance was obtained after further  
point-by-point analysis comparing individual doses of PE between the control and 24 h group, at the 
three highest dosages of PE (10−6–10−4 M) (Figure 6b). These results indicate a possible alteration of  
α-adrenergic responsiveness to high dosages of PE 24 h after MWCNT inhalation. 
Responses to PE, when the highest dosages were compared independently between the control and 
24 h time point, were statistically significant (Figure 6b). When analyzing this outcome, there are four 
points that must be considered, this may be an avenue of additional exploration. First, what is the 
biological relevance or physiological impact to coronary blood flow regulation at these dosages? To 
consider this point, one should keep in mind the distribution of α-1-adrenergic receptors within the 
coronary microcirculation [45,46]. Second, is it physiologically meaningful to compare these PE 
dosages or are these supraphysiological dosages useful to further investigate mechanistic outcomes? 
Third, is this a true physiological difference 24 h after MWCNT inhalation? Lastly, could this be a 
protective compensatory mechanism associated with significant endothelial-dependent dysfunction to 
maintain coronary perfusion? This could indeed be a protective mechanism, as arachidonic acid 
signaling is possibly shifted toward greater thromboxane production leading to an overall constrictive 
environment; perfusion is maintained by dampening other constrictive signals. 
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Figure 6. (a) Phenylephrine time-course dose response curve 24–168 h after control  
(n = 8 rats) or MWCNT inhalation (n = 7–9 rats). Values are mean ± SE. Time course 
evaluation does not reveal any significant differences between control and MWCNT 
exposed rats. (b) Responsiveness to phenylephrine of control (n = 8 rats) vs. MWCNT  
(24 h post-inhalation; n = 7 rats) coronary arteriolar smooth muscle. Values are mean ± SE. 
There are significant differences between control and rats exposed to MWCNT via 
inhalation after 24 h at the highest concentrations of PE. 
 
(a) (b) 
2.4.3. Active Pressure Response 
There were no significant differences in the myogenic responsiveness to pressure alterations 
between 0 and 90 mm Hg (Figure 7), indicating that the sub-epicardial arterioles are able to respond 
appropriately to changes in arteriolar transmural pressure after MWCNT inhalation. 
Figure 7. Myogenic responses of coronary arterioles 24- to168 h after control (n = 10 rats) 
or MWCNT inhalation (n = 7–13 rats). Values are mean ± SE. Data indicate no significant 
differences to active pressure responses after MWCNT inhalation. 
 
Myogenic responsiveness was evaluated as a contributor to tissue autoregulation. The inability for a 
microvessel to accurately conduct and transduce force could have dire tissue perfusion consequences. 
Altered myogenic regulation has been shown in many pathological states, including hypertension, 
which may ultimately lead to an increase in total peripheral perfusion [47]. This responsiveness and 
autoregulatory assessment could not have been accurately attained if the vessels were not permitted to 
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develop spontaneous tone and instead were preconstricted above physiological norms. In this  
study, myogenic responsiveness was maintained at all time points over changes in transmural  
pressure, indicating compensatory mechanisms may be activated to maintain autoregulation, despite  
endothelial dysfunction. 
2.5. Schematic Representation 
Overall, our group has developed a schematic representing the mechanistic alterations leading  
from pulmonary exposure to cardiovascular implications that may contribute to morbidity and  
mortality rates (Figure 8). In this depiction, a pulmonary exposure stimulates bronchoalveolar 
inflammation [21,22,25,48,49].  
Figure 8. Schematic representation of mechanistic alterations initiated by xenobiotic 
pulmonary exposure leading to cardiovascular impairments. The key point of this 
schematic is that no single pathway or mechanism leads to the cardiovascular outcomes 
described within the literature. Additionally, interactions between the pathways may  
exist and account for the temporal maintenance of these consequences. Furthermore, 
consequences in terms of morbidity or mortality are not likely to be seen in young,  
healthy populations. Rather, these events may be contributing to or exacerbate a  
pre-existing condition. 
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At this point, there are three routes which may influence cardiovascular function, leading to 
increases in morbidity and mortality rates [50]. First, the inflammatory route hypothesizes an 
activation of PMN, leading to the release of myeloperoxidase (MPO) and an increase in reactive 
species, which scavenge bioavailable NO [20,48]. Secondly, translocation or direct interaction may 
initiate redox chemistry within the vasculature, as these ENM may be manufactured from or coated 
with a variety of highly reactive materials capable of producing reactive species or reducing 
antioxidant competence within a physiological environment [16,51,52]. Lastly, the neural route may 
stimulate sensory neurons leading to altered afferent and efferent signaling patterns ultimately 
effecting the maintenance of smooth muscle tone [53,54]. These pathways are not isolated or 
independent of each other and they may operate in conjunction with the other routes. For example, a 
translocated particle may embed in tissue (as evident in Figure 2), causing a localized inflammation 
and influencing the inflammatory route, leading to the same systemic vascular outcome. 
These cardiovascular results may not manifest severely in the young healthy models traditionally 
evaluated; however, in compromised models of cardiovascular disease, such as diabetes, metabolic 
syndrome, hypertension, angina, and/or hypercholesterolemia, these exposures may intensify or 
worsen pre-existing conditions. Combining these exposures and pre-existing conditions with an 
increase in physical activity, as during exercise or occupational activity, and the possibility exists for 
the development of a public health storm leading to increases in morbidity and mortality rates 
described in epidemiological literature [55–58]. 
3. Experimental Section 
3.1. Experimental Animals 
Specific pathogen free male Sprague Dawley [Hla:(SD)CVF] rats (7–8 weeks old) were purchased 
from Hilltop Laboratories (Scottsdale, PA, USA). Rats were housed in an AAALAC approved animal 
facility at the National Institute for Occupational Safety and Health in laminar flow cages under 
controlled temperature and humidity conditions and a 12 h light/dark cycle and acclimated for 5 days 
before use. The animals were monitored to be free of endogenous viral pathogens, parasites, 
mycoplasms, Helicobacter and CAR Bacillus. Animals were housed in ventilated cages which were 
provided HEPA-filtered air, with Alpha-Dri virgin cellulose chips and hardwood Beta-chips used as 
bedding. The rats were maintained on a ProLaB 3500 diet and tap water, both of which were provided 
ad libitum. To ensure that all methods were performed humanely and with regard to alleviation of 
suffering, all experimental procedures were approved by the Institutional Animal Care and Use 
Committees of the West Virginia University and the National Institute for Occupational Safety  
and Health. 
3.2. Engineered Nanomaterials 
The MWCNT material was provided by Mitsui & Co. (MWNT-7, Lot # 061220-31, Ibaraki, Japan) 
and has been previously characterized by our group [21,28]. The nanotubes were catalytically grown 
by chemical vapor deposition processes. The powder was conductive and contained nanomaterials of 
fiber-like shape containing an extremely high purity (>99.5%) of carbon with a trace amount of iron. 
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The average width of the primary particles was between 40 and 90 nm (mean = 49 nm), while the 
length varied and could be up to several micrometers (mean = 3.9 µm). The specific surface area was 
24–28 m2/g. 
3.3. Inhalation Exposure 
We have previously reported and described the MWCNT aerosol generator exposure system used 
for inhalation exposures in the current experiments [59]. Briefly, the inhalation system was developed 
for small rodent inhalation particulate exposure. It consists of an acoustic generator, an animal housing 
chamber, many monitoring devices, and feed-back control. The MWCNT aerosol generator includes a 
large acrylic cylindrical chamber enclosed by flexible latex rubber diaphragms. The MWCNT were 
placed on the lower diaphragm, inside the chamber. The chamber was mounted vertically above a high 
compliance loudspeaker facing upwards, acoustically coupling the chamber and speaker. The speaker 
was computer operated (LabVIEW 7.1, National Instruments: Austin, TX, USA) using an analog 
signal through an audio amplifier (Butt Kicker, model BKA-1000-4A) which varied between 10 and 
18 Hz over a 20-s period allowing aerosolization of the MWCNT from the diaphragm. The aerosol 
within the rat exposure chamber was continuously monitored with a Data RAM to allow real time 
feedback concentration control. Clean dry air entered low into the chamber allowing the smallest of 
these aerosolized ENM to exit through a tube at the top of cylinder, while larger agglomerates 
remained in the lower portion. These well dispersed aerosolized MWCNT (Figure 9) were directed to 
an animal exposure chamber at 5 mg/m3 (Figure 10), while a variety of instruments were used to 
characterize the aerosol: a Data RAM (DR-40000 Thermo Electron Co, Franklin, MA, USA) for 
monitoring the mass concentration in real time, a combined APS/SMPS device (TSI, Shoreview, MN, 
USA) for monitoring the particle size distribution of the aerosol, a MOUDI (MSP, Shoreview, MN, 
MN, USA) for measuring mass-based aerodynamic size distribution, and two air filters to provide 
gravimetric measurements. In addition, temperature, relative humidity, pressure and airflow rate in the 
chamber were monitored, controlled and recorded by a computer throughout the 5 h exposure.  
Figure 9. Electron microscopy image of aerosolized MWCNT. 
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Figure 10. MWCNT aerosol generation maintained at 5 mg/m3 for the 5 h exposure. 
 
Rats were exposed (5 mg/m3, 5 h/day) for 1, 3, or 4 days to obtain three different lung burdens 
(13.5, 40.1, and 54.1 µg/lung) for pulmonary dose response studies. These lung burdens were 
determined based on mouse methodology previously reported by our group [49] and normalized to rat 
minute ventilation. Coronary microvascular response was initially evaluated at these three lung 
burdens. However, microvascular data reported in this manuscript were at the lowest lung burden  
(13.5 µg/lung) as microvascular inhibition was attained at this low dosage. After inhalation exposures, 
all rats recovered for at least 24 h prior to experimental procedures. 
3.4. Pulmonary Inflammation 
3.4.1. Bronchoalveolar Lavage  
At 1-day post-exposure, the animals were euthanized with an i.p. injection of sodium pentobarbital 
(>100 mg/kg body weight) and exsanguinated by cutting the descending aorta. A tracheal cannula was 
inserted and BAL was conducted [60]. The first lavage wash contained a 6 ml aliquot of cold Ca+2 and 
Mg+2-free phosphate buffered saline (PBS), which was flushed into and out of the lungs twice before 
the lavage fluid was collected. After the initial lavage wash, the BAL continued with 8 mL aliquots of 
cold Ca+2 and Mg+2-free PBS until an additional 80 mL of bronchoalveolar lavage fluid (BALF) was 
collected. The BALF was then centrifuged at 600 × g for 10 min using a Sorvall RC 3B Plus 
centrifuge (Sorvall Thermo Electron Corporation, Asheville, NC, USA). After centrifugation, the 
supernatant from the first lavage wash was decanted into a clean conical vial and was stored on ice to 
be used for cytotoxicity analysis. The supernatant from the subsequent lavage washes was discarded. 
The pelleted cells from all lavages were washed with cold Ca+2 and Mg+2-free PBS and respun at  
600 × g for 10 min after which the supernatant was discarded and the cells were resuspended in 1 mL 
of HEPES buffer.  
3.4.2. Cell Counts and Differentials 
BAL cell counts were conducted according to their unique cell diameters, using an electronic cell 
counter (Beckman Coulter Multisizer 3 Counter, Hialeah, FL, USA). Cytospin preparations of the 
BAL cells were made using a cytocentrifuge (Shandon Elliot Cytocentrifuge, London, UK). The 
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cytospin preparations were stained with modified Wright-Giemsa stain, and cell differentials we 
determined by light microscopy [21]. 
3.4.3. BAL Fluid Lactate Dehydrogenase Activity and Albumin Concentration 
The degree of cytotoxicity induced by the inhaled MWCNT was determined by lactate 
dehydrogenase (LDH) activity in the BAL fluid from the initial wash. LDH activity was measured 
using Roche COBAS MIRA Plus chemical analyzer (Roche Diagnostic Systems Inc., Branchburg, NJ, 
USA). The alveolar air/blood barrier damage was determined by the concentration of albumin in the 
BAL fluid. BAL fluid albumin concentrations were measured using a CobasFara II Analyzer (Roche 
Diagnostic Systems, Montclair, NJ, USA) as previously described [60].  
3.5. Enhanced-Darkfield Light Microscopy Imaging of Nanoparticles 
Following sacrifice, organs were removed, sliced into 2–3 mm thick tissue blocks and fixed by 
immersion. Tissue blocks were prepared for lung, heart, kidney, and liver. After overnight fixation, 
tissue blocks were embedded in paraffin and sectioned at 5 micron thickness. Sections were collected 
on ultrasonically cleaned, laser cut slides (Schott North America, Inc., Elmsford, NY, USA) to avoid 
nanoparticle contamination from the ground edges of traditional slides. To enhance contrast between 
tissue and MWCNT, sections were stained with Sirius Red. Sirius Red staining consists of immersion 
of the slides in 0.1% Picrosirius solution (100 mg of Sirius Red F3BA in 100 mL of saturated aqueous 
picric acid, pH 2) for 1 h followed by washing for 1 min in 0.01 M HCl. Sections were the briefly 
counterstained in freshly filtered Mayer’s hematoxylin for 2 min, dehydrated, and coverslipped.  
The optical system used for enhanced-darkfield imaging consisted of high signal-to-noise, 
darkfield-based illumination optics adapted to an Olympus BX-41 microscope (CytoViva, Auburn, AL, 
USA). After alignment of the substage oil immersion optics with a 10× objective, the entire area of 
each section was scanned at 20× to detect any MWCNT. Any potential MWCNT identified at low 
power were confirmed by examination at 100× oil immersion objective. Enhanced darkfield images 
were taken with a 2048 × 2048 pixel digital camera (Dage-MTI Excel digital camera XLMCT, 
Michigan City, IN, USA). Additional details on preparation and imaging of MWCNT in tissue sections 
have previously been described [9].  
Counts of the number of MWCNT fibers identified in each section and the cross-sectional area were 
tabulated for each tissue block. The number of MWCNT per unit volume was determined by dividing 
the counts of fiber number by the volume (tissue area × section thickness) of each block used in 
counting. The results were expressed as number of MWCNT in each organ determined by multiplying 
the number of MWCNT per unit volumes times the specific organ volume.  
3.6. Isolated and Perfused Sub-Epicardial Microvessel Preparation 
Rats were anesthetized with isoflurane (5% induction, 2% maintenance) and the heart was removed, 
flushed of excess blood, and placed in a dish of chilled (4 °C) physiological salt solution (PSS) at 24-, 
72-, 120-, or 168 h post-inhalation as previously described by our laboratory [19,41]. Briefly, coronary 
resistance arterioles (<160 µm maximum diameter) were isolated from the left anterior descending 
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(LAD) artery distribution, transferred to a vessel chamber (Living Systems Instrumentation, 
Burlington, VT, USA) containing fresh oxygenated PSS, cannulated with glass pipettes, and secured 
using nylon suture (11-0 ophthalmic, Alcon, UK). Arterioles were extended to their in situ length, 
pressurized to 45 mm Hg with physiological salt solution (PSS), superfused with warmed (37 °C) 
oxygenated PSS at a rate of 10 mL/min, and allowed to develop spontaneous tone [41,61]. Vessel 
diameters were measured using video calipers (Colorado Video, Boulder, CO, USA).  
Following equilibration, arteriolar reactivity was randomly evaluated to ensure that responses were 
neither interactive nor time-dependent in response to: (1) pressure changes to elicit a myogenic 
response, i.e., reductions and increases in pressure from 0 mm Hg to 90 mm Hg at 15 mm Hg 
increments; (2) acetylcholine (ACh) (10−9–10−4 M); (3) sodium nitroprusside (SNP) (10−9–10−3 M);  
(4) phenylephrine (PE) (10−9–10−4 M); and (5) the calcium ionophore, A23187 (10−9–10−5 M). 
Following assessments of arteriolar reactivity, the superfusate was replaced with Ca2+-free PSS until 
passive tone could be established. 
3.7. Formulae and Statistical Analysis 
Data are expressed as means ± SE. Spontaneous tone was calculated by the following equation: 
[(DM − DI)/DM] × 100, where DM is the maximal diameter recorded at 45 mm Hg under Ca2+-free PSS 
as described above, and DI is the initial steady-state diameter achieved prior to experimental period. 
Vessels were used for experiments only if spontaneous tone ≥20% was achieved. Active responses to 
pressure changes were normalized to the maximum diameter as previously described: Normalized 
Diameter = DSS/DM, where DSS is the steady-state diameter maintained at each pressure phase [41]. 
The experimental responses to ACh, A23187, SNP, and PE are presented as percent of relaxation from 
baseline diameter: [(DSS − DCON)/(DM − DCON)] × 100, where DSS remains the steady-state diameter 
achieved after each chemical bolus, and DCON is the control diameter measured immediately prior  
to the dose-response experiment. All experimental periods were at least 2 min in duration, and  
all steady-state diameters were collected for at least 1 min. Representing the responses in  
this manner allowed us to normalize for potential differences in baseline diameters before each  
dose-response curve.  
Statistical comparisons were made at 24 h post-inhalation (5 mg/m3, 5 h) for dose response values 
of percent maximum dilation from treatment of vessels with ACh, A23187, myogenic reactivity, 
phenylephrine, and SNP between air and MWCNT-exposed groups. These comparisons were made 
using a repeated measures analysis of variance (ANOVA) approach with SAS PROC MIXED (SAS). 
This analysis approach allows for the correct specification of a within subject’s correlation structure 
and also accommodates unequal variances between CONTROL and MWCNT treatments. The 
repeated effect was within animal over dose of ACh etc., and an autoregressive correlation structure 
over increasing dose was found to best fit these data. The ANOVA model was based on a two way 
treatment structure with nanoparticle (CONTROL vs. MWCNT) as the first factor and dose of ACh 
etc. as the second factor. The overall test for significance was for a treatment by dose interaction 
followed by post –hoc comparisons at each dose level.  
Statistical comparisons were also made for the linear part of each dose response curve using a 
random coefficient model that allows estimation of a dose response slope for each subject and provides 
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an aggregate comparison of the dose response slopes between treatments at each follow-up time. This 
allowed for comparison of the mean linear dose slopes between CONTROL and MWCNT for each 
follow-up time.  
4. Conclusions 
There are five key findings in this study. First, MWCNT inhalation can acutely cause pulmonary 
inflammation at lung burdens as low as 13.5 µg/lung within a rat model (Figure 1). Secondly, 
MWCNT can translocate at a very low rate out of the lungs and be visualized within other organ 
systems (liver, kidney, and heart) 24 h after inhalation exposure (Figure 2). Third, MWCNT inhalation 
leads to profound alterations to sub-epicardial endothelium-dependent dilation within 24 h  
(Figures 3 and 4). Although this dysfunction partially dissipated over time, it did not fully return to 
baseline levels within 168 h. Fourth, endothelium-independent responses to SNP (Figure 5) and PE 
(Figure 6a), which evaluate vascular smooth muscle sensitivity to nitric oxide signaling and  
α-adrenergic signaling respectively, remained unaltered after MWCNT exposure with respect to time, 
indicating that the coronary microvascular smooth muscle NO and adrenergic sensitivities were intact 
and reactive. Lastly, mechanotransduction (myogenic responsiveness) also remains intact (Figure 7). 
Collectively, these results are the first to report coronary microvascular dysfunction after MWCNT 
inhalation, a condition which persists at least 168 h after exposure.  
There are many avenues which remain for further exploration: (1) evaluation of the underlying 
mechanisms leading to endothelium dysfunction after MWCNT exposure; (2) identification of the time 
point of greatest dysfunction (may be less than 24 h) and a return to baseline (past 168 h);  
(3) examination of the microvascular effects of other routes of MWCNT exposure (injection, gavage), 
assessing gender differences associated with ENM exposure, and4) evaluation of epigenetic concerns 
associated with maternal ENM exposure. Lastly, since diverse ENM are produced at a rate faster than 
their toxicological assessments can be made, high throughput predictive screening tests should  
be explored.  
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